South Florida trauma nurse proves it's never too late to follow your dreams
At Broward Health Medical Center, trauma nurse Traci Vose is no stranger to high-pressure situations, but her story goes beyond the hospital walls.
"Serving a greater cause on both sides, both the military and civilian life," she said. "I love to help people, I want to serve people, and I'm gonna keep doing that 'til my body says stop."
After many years as a single mom and spending more than a decade caring for the sick, Vose decided to enlist in the U.S. Navy Reserve at the age of 49.
It wasn't easy. She faced rejection multiple times.
"The age waiver, I surpassed that by several years, and the noes disheartened me, but my team here at Broward kept encouraging me," Vose said. "I felt called to do it, so I wasn't going to give up until someone said yes."
Following in a family tradition
When a "yes" finally came, it was an emotional one.
"I cried," Vose said. "This has been a lifelong dream for me to do it. And to be able to serve my country just like my family has, was a huge honor for me."
Vose's husband, children and others in her family also served.
Never too old to pursue your dreams
Her service took her to Africa, where she applied her trauma nursing skills. Now back home, she blends lessons learned on the battlefield with hospital care, while also inspiring others.
"I came across a lot of people, especially in officer candidate school, who were much younger than me," Vose said. "And to see somebody who could be their mother out there, you know, going above and beyond to pursue this dream of mine, they were inspired by that."
Vose serves one weekend a month and is preparing for another deployment next year. Her story is a powerful reminder that dedication knows no age limits and it's never too late to follow your dreams.
"Resiliency and never giving up," she said. "If you have a passion and a dream, you find that yes. If someone's telling you no, you're not talking to the right person."
Send us your story at MiamiProud@cbs.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
1 Stock Down 40% This Year to Buy and Hold
Key Points Novo Nordisk's shares have been trending downward due to clinical setbacks and underwhelming results. However, the company has some potential catalysts on the way that could jolt its stock price. Novo Nordisk looks attractive given its lineup and pipeline, especially at current levels. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) first earned U.S. approval for its now-famous weight management medicine Wegovy in June 2021. That marked the beginning of a strong run for the company on the stock market. However, the Denmark-based drugmaker has given up most of these gains over the past year; the stock is down by 40% since January alone. Despite its recent misfortunes, Novo Nordisk's shares could still deliver strong returns to patient investors. Here's why. The weight management opportunity Novo Nordisk primarily develops medicines for diabetes and, in recent years, weight management. Its stock has plunged over the past year because its financial results haven't been as impressive as the market had hoped. It also faced some clinical setbacks, while its biggest rival in its core markets, Eli Lilly, earned some important wins. However, there's more to the story. The market for anti-obesity medications could grow at an incredibly rapid rate. Some analysts estimate that it will be worth $150 billion by 2035, compared to $15 billion last year. Novo Nordisk still has one of the deepest pipelines in the industry. In fact, it's challenging to find a company other than Eli Lilly that has more promising products. Recently, Novo Nordisk expanded its pipeline through various licensing deals. Here's one more thing that recently broke its way: Eli Lilly's oral GLP-1 candidate, orforglipron, did not perform nearly as well as expected in a phase 3 study. This opens the door for Novo Nordisk to catch up to its longtime rival. The company's oral version of Wegovy is currently awaiting approval from regulators in the U.S. The oral version led to an average weight reduction of 13.6% in a phase 3 clinical trial, slightly higher than the 12.4% that orforglipron recently posted in its late-stage study. While it's always hard to compare across clinical trials, the data at the very least suggests that oral Wegovy is comparable to orforglipron -- but only the former drug is closing in on approval. Novo Nordisk also has yet another promising anti-obesity candidate in phase 3 studies, amycretin, which the Denmark-based pharmaceutical giant is testing in both subcutaneous and oral formulations. Why is the race to develop an oral weight loss option so important? Pills are easier and cheaper to manufacture, store, and transport. So, compared to injectable weight loss therapies, oral versions would allow drugmakers to produce them more cost-effectively and to expand the reach of weight loss therapies. On top of that, some patients are strongly averse to needles. Because the current leading weight management drugs are administered subcutaneously, an oral option would likely take a decent share of the market. Novo Nordisk is likely to be first to market. And the company could follow up that win with another oral product in amycretin. The price is right Let's go back to Novo Nordisk's recent and disappointing financial results. In the first half of the year, revenue rose by 16% year over year to 154.9 billion Danish kroner ($24.2 billion), while net profit came in at 55.5 billion DKK ($8.7 billion). Perhaps that's not quite what the market expected to see, but these are still excellent results for a pharmaceutical giant -- most drugmakers of that size would be happy to grow their revenue at high-single-digit or low-double-digit rates. Meanwhile, the stock appears reasonably valued, trading at 13 times forward earnings, compared to the healthcare industry's average of 16.2. What's the verdict? Novo Nordisk looks attractive at current levels, given the company's strong pipeline in weight management and a lineup that continues to deliver consistent profits. Despite recent setbacks, the stock is well-positioned to deliver excellent results over the long term. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 1 Stock Down 40% This Year to Buy and Hold was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
If You're in Your 30s, Consider Buying These 2 Healthcare Stocks
Key Points Intuitive Surgical leads the robotic-assisted surgery market and benefits from long-term trends. Moderna is an innovative vaccine maker which saw success in the pandemic and has a deep pipeline. Both stocks could help investors in their 30s achieve substantial returns over the long term. 10 stocks we like better than Intuitive Surgical › Investing styles tend to evolve as people age. Seniors who are already retired often look for steady, reliable, dividend-paying companies. Younger investors, on the other hand, can afford to take more risks and tend to seek out companies that, despite being more volatile, also boast significant long-term upside potential. With that in mind, let's consider two stocks that people in their 30s -- who are still a good distance away from retirement -- should consider investing in: Intuitive Surgical (NASDAQ: ISRG) and Moderna (NASDAQ: MRNA). 1. Intuitive Surgical Intuitive Surgical is a medical specialist that leads the market for robotic-assisted surgery (RAS) devices, thanks to its famous da Vinci system, which is by far its most important growth driver. This machine enables physicians to perform minimally invasive surgeries across a range of approved indications, including bariatric, urologic, and general surgery. The company has faced several challenges over the past few years, including a decline in bariatric surgeries due to the growing popularity of anti-obesity medications, and the threat posed by the Trump administration's tariffs. Despite those problems, its long-term prospects look incredibly attractive. One reason is that Intuitive Surgical has a resilient business. The company has achieved excellent results over the past five years, with consistently growing top- and bottom-line numbers: Another great reason to remain bullish on the company's long-term prospects is that its addressable market still looks underpenetrated. Intuitive Surgical makes more than half of its revenue from sales of instruments and accessories, which are tied to procedure volume. The more surgeries physicians perform with its devices, the higher its sales. Thus, Intuitive Surgical will benefit from demographic changes that are happening right under our noses, as the world's population ages. By the time investors in their 30s retire, a much higher proportion of the population will be seniors who are in greater need of the kinds of procedures Intuitive Surgical offers. Furthermore, even with mounting competition, the company benefits from a wide moat due to switching costs (da Vinci systems are expensive) and intangible assets, namely patents that protect its inventions. Intuitive Surgical has consistently outperformed the market over the past 25 years, and it's likely to continue doing so, helping younger investors significantly grow their capital over time. 2. Moderna Moderna is a riskier bet than Intuitive Surgical, but the biotech also has significant upside potential. The vaccine maker demonstrated its innovative capabilities by developing one of the most successful COVID-19 vaccines on the market. Several pharmaceutical leaders tried and failed, but Moderna succeeded; that's saying something. The company's mRNA platform is attractive because vaccines based on it tend to be faster and cheaper to develop. And since its success in the coronavirus space, Moderna has recorded several clinical and regulatory wins. It earned approval for a vaccine for respiratory syncytial virus (RSV) and recorded phase 2 or phase 3 wins for vaccines against influenza, influenza plus COVID, and even cancer. Why, then, has the stock significantly lagged the market over the past three years? Moderna's coronavirus vaccine franchise is no longer generating the sales and profits it once did. The company's shares probably rose too much too fast in the early pandemic years, meaning a sell-off was justified. However, now Moderna could take off and deliver superior returns over the long run, provided it continues to innovate. To that end, the company's pipeline looks attractive, with potential candidates across even ambitious targets. Moderna's personalized cancer vaccine, mRNA-4157, which helped decrease the risk of recurrence and death in melanoma patients in phase 2 studies, is now in late-stage clinical trials. The company is targeting many other cancers, and is even working on a potential HIV vaccine that's in early-stage clinical trials. While mRNA vaccines are still relatively new to the market, if Moderna manages to make them mainstream by launching several over the next five years, there could be a massive upside for the stock. Again, it's a riskier bet, but investors in their 30s who can handle the volatility should seriously consider Moderna. Should you buy stock in Intuitive Surgical right now? Before you buy stock in Intuitive Surgical, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Intuitive Surgical wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Intuitive Surgical. The Motley Fool has positions in and recommends Intuitive Surgical. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. If You're in Your 30s, Consider Buying These 2 Healthcare Stocks was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
This Gen Alpha Trend Has Millennials Wondering If They Just Spent Their Entire Childhoods Dehydrated
Kids these days never leave home without their fancy water bottles and Stanley cups — it's a whole THING. They are basically walking hydration stations. It's a stark contrast to the way a lot of millennials grew up. Recently Reddit user GetnLine asked the question that's been on a lot of millennials' minds: "were we dehydrated through our childhood?" "As I look at kids in school today, they all have huge water bottles that they carry around, and let's not even speak on those Stanley cups. Meanwhile, if I wanted water while in school, I had to walk to the water fountain in the middle of the hallway. Thinking back to my school days, I probably drank from that water fountain once or twice a day, and the only other thing I drank was milk at lunch. So, were we dehydrated and just didn't notice it?" A lot of people agreed that they don't really remember drinking water: "I don't remember purposely drinking water as a child. Juice or Kool-Aid, sure. Just water? Only from the hose, ironically." —WellWicced "When my brothers and I first met our cousins in Florida, it absolutely blew our minds that they drank water. Like, on purpose. Until that point in my life, I couldn't recall anyone ever voluntarily consuming plain water except as a last resort." —kendalltristan "I talked to my mom about this, and she said she doesn't remember drinking water or really giving us water or really anyone caring about drinking water until Oprah started talking about it, lol." —Fuck_auto_tabs "I remember thinking in high school, 'I can't wait 'til I'm an adult so I can carry a water bottle everywhere and take a drink whenever I want one!' True story." —SparkleShineGlitter Although, there was a limited supply from school water fountains, of course: "If the whole class went to the water fountain there was a teacher standing there counting '1,2,3 you're done.'" —glitterr_rage "I just had a flashback to the entire line yelling 'save some for the fishes!' if you took too long." —Petal170816 "I remember being so hot and so thirsty after gym class. A three-second warm-ass drink from a stank fountain was all we got. I carry a big-ass water bottle with me too these days, haha." —cactuschili "I got yelled at and sent to timeout by a gym teacher because I asked for a drink of water during gym class outside on a hot day. I was 7 years old." —NeitherPot "I remember there were some kids who put their entire mouth directly in the fountain. It was super gross." —Cold_Coconut4079 Mostly, people drank things that weren't water back in the day... "I survived on grape Kool-Aid. It was made from water, so it counts, right?" —cuppa_cat "Either Juicy Juice (100% actual juice) or Hawaiian Punch (maybe at best 10% juice, but still delicious)." —rizzesblackcloud "Does anyone remember TANG? I loved that shit." —Skelligean "Country Time lemonade here…like a gallon a day." —Similar-Lie-5439 "I survived on milk. Hated the taste of water and refused to drink it unless I was about to pass out from dehydration and there was no other option." —Ilaxilil And yes, everyone was probably dehydrated: "I used to get the worst dehydration headaches. I can't remember the last time I had one." —HyperSaurus "My mom took me to the pediatrician and eye doctor for my chronic headaches. Finally, after nothing worked, my pediatrician recommended just drinking more water and Gatorade. Cut the headaches in half." —allnightdaydreams "I had to get a doctor's note to carry a water bottle because dehydration was exacerbating my heart condition. My teacher still sent me to the office for having one!" —kilowatkins "For years I struggled to poop. Turns out being hydrated can cure that! Not a single doctor or any adult put this together…" —Kattymcgie "I used to have 'fainting spells' as a child often, and it was always dehydration." —StickerProtector "I would wake up in the middle of the night with those charlie horse leg cramps all year long, but it became especially bad during softball season. Oof, I drank so little water and so much Mountain Dew." —MercyTheCat Can you relate to this?! Did we all just spend our childhoods really, REALLY dehydrated? Do you now carry an emotional support water bottle as a result? Tell me all about it in the comments. Note: Responses have been edited for length/clarity. Solve the daily Crossword
